First partner validation of vamorolone in DMD through a lucrative licensing agreement with Sperogenix for the Greater China Region in a deal valued at USD 124 mn plus double-digit sales royalties. Vamorolone US and EU DMD filings are on track for H1 2022. Santhera provides substantial equity upside while vamorolone in DMD has been largely de-risked.
Key catalysts include
Read full Santhera Valuation Report "On a mission with a VISION" update